How do you know the drug you are using is safe and effective?
|
|
- Gervais Manning
- 5 years ago
- Views:
Transcription
1 The Chemistry, Manufacturing, and Controls (CMC) Technical Section: The Big Picture of a Long-term Commitment AAVPT Workshop February 28, 2011 James K. Nitao, Ph.D. Biotherapeutics Team Division of Manufacturing Technologies U.S. FDA, Center for Veterinary Medicine How do you know the drug you are using is safe and effective? Because clinical studies demonstrated the drug is safe and effective? Hypothetical Timeline of a Drug s Life: 1999: Drug batches are made for clinical studies 2005: CVM approves the drug for marketing 2006: Drug product manufacturing moved from New Jersey to Missouri Clinical studies demonstrate that the drug is safe and effective First commercial batches are manufactured and sold to the public 1
2 2008: Product expiry extended from 12 to 24 months 2009: New stopper composed of different polymer 2010: Major renovations made to the aseptic fill facility Moved sterilization of vials and stoppers to another facility New HPLC method used to test drug prior to release Active ingredient manufacturing moved from US to China Summary: Eleven years ago, safety and effectiveness studies were performed using a drug made in a New Jersey facility, and formulated with an active ingredient made in the U.S. Today, the drug is made in a different facility using different equipment and procedures, with an active ingredient made by a different company (located overseas), and with containers made with different materials. How do you know - Impurity levels are still being adequately controlled? - The new HPLC method accurately measures the potency of the drug? - The new stopper adequately seals the vial after multiple needle punctures (if the drug is packaged in a multi-dose container)? - The current depyrogenation procedure still removes endotoxins from the new stopper polymer? - The drug and its container components are sterile? 2
3 How do you know the drug you are using is still safe and effective? Are clinical studies by themselves sufficient to assure the safety and effectiveness of a marketed drug? A well designed and controlled manufacturing process is needed to assure product quality and consistency from unit dose to unit dose from vial to vial from batch to batch Potency Which drug do you want to be using? Batches Batches 3
4 Why is there a CMC section? To assure that the drug sold to the public will have quality attributes similar to those of the drug demonstrated to be safe and effective To assure that the quality of the drug meets appropriate standards and is consistent To assure that the drug you are using is the drug described on the label CMC technical section How and where is the drug made? How are raw materials tested and monitored? What control procedures are in place to assure product consistency and quality? Are quality attributes adequately identified and characterized for the product? Are the test methods used to monitor product quality appropriate? How long does the product maintain its quality after it is made (shelf life)? Drug used in clinical studies Safe and effective CMC helps maintain the connection in quality between the drug used in clinical studies and the marketed drug Drug marketed to consumers Commercial product 4
5 Clinical Batches Safety and effectiveness studies Pilot Batches CMC information Engineering Batches Scale-up from pilot to commercial Process Validation Batches Implementation of commercial manufacturing processes Commercial Batches Product marketed to consumers Batches at each stage should be made using the same or similar processes and raw materials CMC is Specific to the Product How is the product sterilized? Is the sterilization process validated? Is the manufacturing environment monitored to control microbial contamination? How is sterility of the finished product monitored? Does the vial and stopper keep the product sterile? How is the vial and stopper depyrogenated? If the container is used for multiple doses, does the stopper keep the product sterile after punctured? Is a preservative needed in the formulation? Process Understanding is Vital to Quality and Consistency Testing of the finished drug product alone is insufficient for control of product quality The manufacturer should know which steps and variables in the manufacturing process need to be controlled and why Process understanding is the foundation of a controlled manufacturing process 5
6 Quality Attribute A manufacturing process under control exhibits consistency of product quality Batches Batches Current Good Manufacturing Practices Chemistry, Manufacturing, and Controls CMC review and cgmp compliance may overlap but are not the same Center for Veterinary Medicine Office of Regulatory Affairs Lead office for FDA domestic and foreign field activities including cgmp inspections Division of Manufacturing Technologies (CMC Reviewers) Division of Compliance (Compliance Officers) 6
7 CMC cgmp CVM Division of Manufacturing Technologies reviews the CMC technical section which is not an evaluation of current Good Manufacturing Practices (cgmps) and will request inspections if needed cgmp compliance is assessed by inspections by investigators in the FDA Office of Regulatory Affairs but FDA Centers are involved under certain circumstances District Offices (within the Office of Regulatory Affairs), CVM Division of Manufacturing Technologies, and/or Division of Compliance determine regulatory actions regarding inspections Manufacturing Facilities Every facility should be identified and approved in the CMC section, and every facility must comply with current Good Manufacturing Practices (cgmps) including: Manufacturers of API Manufacturers of finished drug product Contract sterilization facilities Packagers Testing Laboratories Over time, change is inevitable Raw material suppliers Manufacturing sites Manufacturing processes Manufacturing equipment Packaging Specifications Testing procedures But product quality should be constant (or improve) 7
8 Drug used in clinical studies Safe and effective CMC Review of Post-Approval Changes: Will the quality of the marketed product still be similar to that of the drug shown to be safe & effective? Drug marketed to consumers Commercial product The drug sponsor must report CMC changes to CVM for as long as it owns and markets the product Review of Drug Before Approval Drug Approval Post-approval CVM reviews CMC changes and stability data from on-going studies Role of CMC review and generic drugs 8
9 Pioneer (Innovator) Drug The manufacturer of the Generic Drug does not know how the pioneer drug is made or exactly what the components and composition are in the pioneer drug (other than the active ingredient) Generic Drug Pioneer (Innovator) Drug CMC review helps maintain the connection in quality between the pioneer drug and the generic drug Generic Drug CMC review helps assure that Quality is designed into the manufacturing process (and does not rely on testing alone) Quality is maintained as long as the product is marketed 9
10 For More Information: James K. Nitao, Ph.D. Biotherapeutics Team Division of Manufacturing Technologies Office of New Animal Drug Evaluation FDA, Center for Veterinary Medicine 7500 Standish Place Rockville, Maryland (240)
Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.
FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis
More informationHot Topics in Drug Product Process Validation: A Reviewer s Perspective
Hot Topics in Drug Product Process Validation: A Reviewer s Perspective Colleen Thomas, Ph.D. Quality Assessment Lead (Acting) FDA/CDER/OPQ/OPF Division of Microbiology Assessment CASSS CMC Strategy Forum
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationQuestion-based Review (QbR)
Question-based Review (QbR) Rebecca L. Owen, Ph.D. Team Leader, Feed/Topical Team Division of Manufacturing Technologies ONADE/CVM/FDA Outline Background on CMC Filing Requirements What is QbR? QbR at
More informationPHARMACEUTICAL TESTING
WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey
More informationElemental Impurities Update from CVM
Elemental Impurities Update from CVM February 19, 2014 Michael Brent, Ph.D. Center for Veterinary Medicine Division of Manufacturing Technologies, HFV-146 USP and The elemental impurity limits
More informationGMP The Other Side of Chemistry, Manufacturing & Controls (CMC)
Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls
More informationHow we set specifications for impurities (including Genotoxic impurities) 24 May 2017 Elisabeth Kovacs, Apotex CSO Chemistry and Analytical Sci.
2017 AAM CMC Workshop How we set specifications for impurities (including Genotoxic impurities) 24 May 2017 Elisabeth Kovacs, Apotex CSO Chemistry and Analytical Sci. The information within this presentation
More informationAugust 14, Dockets Management Staff (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org August 14, 2018 Dockets Management Staff (HFA-305) Food and Drug Administration 5630
More informationGuidance for Industry
Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products Center for Drug Evaluation and Research (CDER) Center
More informationThe Application of Pharmaceutical cgmp to Live Bacterial Products. James Harris Business Development Manager
The Application of Pharmaceutical cgmp to Live Bacterial Products James Harris Business Development Manager The Objective CMC expectations of a cgmp live bacterial biopharmaceutical project Overview Define
More informationGuidance for Industry
Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationGuidance for Industry
Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationQuality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review
Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical
More informationGuidance for Industry
Guidance for Industry Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Quality DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
More informationCGMP for Phase 1 INDs
CGMP for Phase 1 INDs Laurie P. Norwood Deputy Director Division of Manufacturing and Product Quality Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research 1 Overview
More informationFuture of Question-based Review and Regulatory Submissions
Future of Question-based Review and Regulatory Submissions Robert Iser Associate Director for Policy Development (Acting) Office of Pharmaceutical Science / CDER / FDA FDA/PQRI Conference on Evolving Product
More informationExtending Beyond Use Dating for Compounded Preparations Webinar Q&A
Stability Studies 1. If potency over time studies are not acceptable to extend BUD, then why is it offered? Potency point-in-time studies only indicate the potency of a compounded preparation at that specific
More informationExtending Beyond Use Dating for Compounded Preparations Webinar Q&A
Stability Studies 1. If potency over time studies are not acceptable to extend BUD, then why is it offered? Potency point-in-time studies only indicate the potency of a compounded preparation at that specific
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationGuidance. Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE
Guidance Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and
More informationFSMA Regulations for Ethanol Co-Products
FSMA Regulations for Ethanol Co-Products Kelly Davis Director of Regulatory Affairs Renewable Fuels Association October 2015 About the Renewable Fuels Association Founded in 1981 National Trade Association
More informationEarly Development Best Practices for Stability- Regulatory Perspective
Early Development Best Practices for Stability- Regulatory Perspective IQ Workshop, Feb. 4-5, 2014, Washington, D.C. Ramesh Sood, Ph.D. Division Director (Acting) Office of New Drug Quality Assessment
More informationRegulatory Implications for Global Manufacturing Development of Regenerative Medicines
Regulatory Implications for Global Manufacturing Development of Regenerative Medicines Katherine Tsokas, JD June 2017 Global Regulatory Affairs Janssen Research & Development, LLC Jessica Riley, Shells
More informationThe Role of Chemists in the FDA Drug Approval Process
The Role of Chemists in the FDA Drug Approval Process 231 st ACS National Meeting Atlanta, GA M. Scott Furness, Ph.D. March 26, 2006 Introduction Presentation Outline FDA Organization CDER Organization
More informationA Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products
A Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products Angela Whatley, Ph.D. Office of Tissues and Advanced Therapies CBER/FDA CMC Strategy Forum on Cell & Gene Therapies
More informationUpdates Regarding the OGD Division of Microbiology & ANDA Sterility Assurance Review Dr. Lynne A. Ensor
Updates Regarding the OGD Division of Microbiology & ANDA Sterility Assurance Review Dr. Lynne A. Ensor U.S. Food & Drug Administration Center for Drug Evaluation & Research Office of Pharmaceutical Science/Office
More informationRisk based approaches for a sterility assurance application review: a microbiologist s perspective Dr. Yeissa Chabrier Roselló
Risk based approaches for a sterility assurance application review: a microbiologist s perspective Dr. Yeissa Chabrier Roselló Product Quality Microbiologist Division of Microbiology Assessment Office
More informationAnnex A2. Guidance on Process Validation Scheme for Aseptically Processed Products
Annex A2 Guidance on Process Validation Scheme for Aseptically Processed Products 1 Table of content 1 PURPOSE... 3 2 SCOPE... 3 3 GENERAL INFORMATION... 3 4 INFORMATION NEEDED FOR ASEPTIC PROCESSES VALIDATION...
More informationPROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.
Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation
More informationPre-Approval Inspections for Drug Products
Pre-Approval Inspections for Drug Products FDA Small Business Regulatory Education for Industry Conference June 20, 2013 H.L. Jamillah Selby Consumer Safety Officer FDA, Dallas District Office Presentation
More informationSynopsis: FDA Process Validation Guidance
Synopsis: FDA Process Validation Guidance This synopsis is a comparison of the draft version 2008 and the final version 2011 of the U.S. FDA Guidance Process Validation: General Principles and Practices.
More informationPorton Biopharma Limited 1/17/17
Porton Biopharma Limited 1/17/17 10903 New Hampshire Avenue Silver Spring, MD 20993 Via UPS Warning Letter 320 17 19 Return Receipt Requested January 19, 2017 Dr. Roger J. Hinton Managing Director Porton
More informationSeptember 2, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
September 2, 2014 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: FDA Draft Guidance: Current Good Manufacturing Practice Interim
More informationCMC Consideration for the Development of Regenerative Medical Products
CMC Strategy Forum Japan 2018 December 4, 2018, Tokyo Marriot Hotel, Tokyo, Japan CMC Consideration for the Development of Regenerative Medical Products Kazunobu Oyama, PhD Deputy Review Director, Office
More informationSterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM
Sterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM DCVMN Workshop, Hyderabad, 4-8 April 2016 G. Somasundaram Associate Director - Technology Management Overview Key Regulatory
More informationPre-Approval Inspection Program Update
Pre-Approval Inspection Program Update David Doleski Acting Deputy Director, OPF FDA/CDER/OPQ 2015 GPhA CMC Workshop June 10, 2015 1 Objectives of Office of Pharmaceutical Quality (OPQ) A single unit in
More informationUS FDA: CMC Issues for INDs
ISBTC Global Regulatory Summit October 29, 2008 US FDA: CMC Issues for INDs Keith Wonnacott, Ph.D. keith.wonnacott@fda.hhs.gov US Food and Drug Administration Center for Biologics Evaluation and Research
More informationWhy Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services
Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services Disclosures I, Ross Caputo, declare no conflicts of interest, real or apparent, and
More informationRegulatory Perspective on Assuring Ingredient Quality
Regulatory Perspective on Assuring Ingredient Quality PQRI Conference December 15, 2009 Rockville, MD Steven M. Wolfgang, Ph.D., Acting Associate Director, Regulatory Science US Food and Drug Administration
More informationSession 4: Ensuring Product Quality Throughout the Supply Chain
Session 4: Ensuring Product Quality Throughout the Supply Chain Potential Quality Assurance Checkpoints Within the Overall Supply Chain 1. Raw Materials / Components 2. Manufacturing 3. Packaging 6. Receiving
More informationPhase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017
Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/
More informationProposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding <823>
Proposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding Ravi Ravichandran, Ph.D. Steve Zigler, Ph.D. February 21, 2011 Agenda Rationale for the
More informationCorporate. Established in Acquired facilities of: Competencies across the Generics & Biologics, value chain.
Established in 2013 Acquired facilities of: Corporate Enzon Pharmaceuticals- NJ, USA- 2013 Pfizer- NY, USA- 2016 Competencies across the Generics & Biologics, value chain. Contract Manufacturing Fully
More informationKorea GMP & DMF. April Korea Pharmaceutical Traders Association Deputy director Oh Hyun, Kwon
Korea GMP & DMF April. 2015 Korea Pharmaceutical Traders Association Deputy director Oh Hyun, Kwon Contents 1. KPTA 2. Pharmaceutical industry 3. KGMP 4. KDMF KPTA KPTA Purpose ㅇ Trade promotion of pharmaceuticals,
More informationOctober 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
October 10, 2017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2017 D 2802: Chemistry, Manufacturing, and Controls
More informationOverview of Inspection Issues with Legacy Products
Overview of Inspection Issues with Legacy Products Presented by Simone E. Pitts Consumer Safety Officer, USFDA Team Biologics simone.pitts@fda.hhs.gov Objective To provide some examples of recent inspectional
More informationJournal of Atoms and Molecules
Review article Journal of Atoms and Molecules An International Online Journal ISSN 2277 1247 CLEANING VALIDATION IN PHARMACEUTICAL INDUSTRIES Abhishek Raj Senior R&D Officer, Quest Pharmaceuticals Pvt.
More informationActavis Italy. Nerviano Plant
Actavis Italy Nerviano Plant Starting out in 1901 in Jerusalem The company known today as Teva was established as a small wholesale drug business by Chaim Salomon, Moshe Levin and Yitschak Elstein. (They
More informationThe Complete Solution: Althea s Simplified ADC Supply Chain
The Complete Solution: Althea s Simplified ADC Supply Chain You have the power to make a difference. To make new therapeutics that improve quality of life and inspire a healthier world. To do this, you
More informationBen Venue Laboratories, Inc. 16-Nov-07
Ben Venue Laboratories, Inc. 16-Nov-07 Department of Health and Human Services Public Health Service Food and Drug Administration Cincinnati District Office Central Region 6751 Steger Drive Cincinnati,
More informationCV Mads Friis Sørensen, Elsdyrvej 18, 4623 Lille Skensved
Employment, Company and Position Jan 2007 present CV Pharmac, Founder and Senior GMP Consultant, See. Summary General consultancy for the pharmaceutical industry within the area s of Quality Assurance,
More informationContract Manufacturing Services for Pre-filled Syringes
Contract Manufacturing Services for Pre-filled Syringes From Standard Solutions to Complex Products Stefan Czvitkovich, PhD Director Product Partnering Sterile Pharmaceuticals Central Europe CPhI woldwide
More informationGuidelines for Pharmaceutical Equivalence Requirements
Guidelines for Pharmaceutical Equivalence Requirements Version 1.1 1 September 2010 Page 1 of 9 Guidelines for Pharmaceutical Equivalence Requirements Version 1.1 Drug Sector Saudi Food & Drug Authority
More informationPharmaceutical Reference Standards: Overview and Role in Global Harmonization
Matthew Borer, Ph.D., Advisor Pharmaceutical Reference Standards: Overview and Role in Global Harmonization 3rd DIA China Annual Meeting Beijing, China, 16-18 May, 2011 What is a Pharmaceutical Reference
More informationSurvival Kit for Regulatory Inspections
Creators of the GMP Ready-to-Use Training System Having the FDA or other regulatory agency arrive to conduct an inspection can be stressful, even terrifying! Being caught off-guard can lead to severe consequences.
More informationHow to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER
How to Avoid Common Deficiencies in INDs and NDAs Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER 1 Structure of FDA Office of Commissioner Chief Scientist FOODS Medical Products & Tobacco
More informationStatement of David G. Strunce President and Chief Executive Officer Scientific Protein Laboratories LLC
Photos from SPL Statement of David G. Strunce President and Chief Executive Officer Scientific Protein Laboratories LLC Subcommittee on Oversight and Investigations Committee on Energy and Commerce United
More informationCell Therapy Product Manufacturing Considerations. July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D.
Cell Therapy Product Manufacturing Considerations July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D. Office of Tissues and Advanced Therapies FDA/CBER Overview Establishing Manufacturing Control Applying
More informationBIOPHARMACEUTICAL QUALITY. 18 July 2013 Cynthia H Sarnoski PhD
BIOPHARMACEUTICAL QUALITY 18 July 2013 Cynthia H Sarnoski PhD What is Quality? 2 3 Quality Quality is never an accident; it is always the result of high intention, sincere effort, intelligent direction
More informationDECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE
DECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE Determine impurity level in relevant batches 1 Determine mean + upper confidence limit for the impurity
More informationMarch 4, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
March 4, 2014 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2013-N-1523: Request for Nominations: Drug Products that
More informationElemental Impurities and Animal Drugs An Update from CVM
Elemental Impurities and Animal Drugs An Update from CVM November 2, 2017 Michael Brent, Ph.D. Center for Veterinary Medicine (CVM) Division of Manufacturing Technologies (DMT) This presentation summarizes
More informationMDI Manufacturing Services
MDI Manufacturing Services Presenter, Date Who we are 3M Drug Delivery Systems is a division of 3M dedicated to working together with pharmaceutical and biotech companies to bring new and improved products
More informationQuality Agreements and Managing Contract Supplier Quality
Quality Agreements and Managing Contract Supplier Quality American Society for Quality Lloyd Bailey November 3, 2005 Service Mark of The Dow Chemical Company TM Trademark of The Dow Chemical Company Abstract
More informationJeff Yuen and Associates, Inc. PO Box 6026 Orange, CA Zenaida Power Regulatory Expertise:
Regulatory Expertise: Pharmaceuticals: Sterile-Liquids, Non-Sterile Liquids, Solid Oral Dosage Form, Parenterals, Antibiotics, APIs/Bulk Chemicals, Creams & Ointments Medical Devices: Implantable / Active
More informationICH Q8/Q8(R)
Pharmaceutical Quality for the 21 st Century Temple University May 06, 2008 Joseph Famulare, Deputy Director FDA CDER Office of Compliance CDER Office of Compliance and the Critical Path Initiative Since
More informationVaccine Assessment for Prequalification and Programmatic Suitability for Prequalification
Vaccine Assessment for Prequalification and Programmatic Suitability for Prequalification Dr Drew Meek Prequalification Team/Vaccines Assessment Regulation of Medicines and other Health Technologies World
More informationFDA Drug Compliance. Pepe Rodriguez-Perez, PhD Business Excellence Consulting Inc / BEC Spain SL.
FDA Drug Compliance Presented by Pepe Rodriguez-Perez, PhD Business Excellence Consulting Inc / BEC Spain SL www.calidadpr.com email pepe@calidadpr.com Agenda 1. FDA s Strategic Priorities 2014-18 2. CDER
More informationQ & A on USP General Chapter <823> Revision Proposal Webinar held on 21 February 2011
1. For day of use calibration, why does the chapter recommend only 2 injections of the known standard versus current standard of 3? Response: The current Chapter does not specify a number of standard
More informationICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon
ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon 9 November 2016 Disclaimer The views and opinions expressed in this presentation are those of the author
More informationAncillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach
USP/ISCT Workshop 2012 Seattle, WA, USA Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach Elizabeth Read, MD Head of Product Development
More informationOverview of Generic PET Applications. Sema Basaran, Ph.D. The 34 th Annual High Country Nuclear Medicine Conference.
Overview of Generic PET Applications Sema Basaran, Ph.D. The 34 th Annual High Country Nuclear Medicine Conference. March 1-6, 2013 Disclaimer This presentation reflects the views of the presenter and
More informationPRAXIS. A publication by Bioengineering AG
PRAXIS A publication by Bioengineering AG Portrait of Rentschler Biotechnologie GmbH, a globally active service company that supports its clients in the development, production, and registration of biopharmaceuticals.
More informationOctober 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
October 10, 2017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2017 D 2802: Chemistry, Manufacturing, and Controls
More informationExtractables and Leachables in Early Phase Development
Extractables and Leachables in Early Phase Development Wayland Rushing, Ph.D. Senior Scientific Advisor, ABC 11/23/2015 Product and Process Variants & Impurities 1 Regulatory Perspective Dr. Ingrid Markovic,
More informationDelivery of materials (usually finished product from a distribution center) to a first paying customer external to Site
Title: Cold Chain Management of Biopharmaceutical Materials Guidance Number: 122 Prepared by: Date: Supersedes: Checked by: Date: Date Issued: Approved by: Date: Review Date: Introduction The risk of compromising
More informationTestimony of Molly Ventrelli Vice President, Regulatory Affairs Fresenius Kabi USA, LLC
Testimony of Molly Ventrelli Vice President, Regulatory Affairs Fresenius Kabi USA, LLC U.S. House of Representatives Energy and Commerce Committee Subcommittee on Health Subcommittee January 30, 2018
More informationCHANGE CONTROL MANAGEMENT FOR A STABILITY PROGRAM
Potential Changes and Minimizing the Impact of Registration CHANGE CONTROL MANAGEMENT FOR A STABILITY PROGRAM Kim Huynh Ba Eecutive Director PHARMALYTIK www.pharmalytik.com Biography Kim Huynh Ba has over
More informationSetting Specifications for Biotech Products
Setting Specifications for Biotech Products Session 1: What to Control? Presentation by an EU Regulator Nanna Aaby Kruse, Senior Biological Assessor, member of BWP and BMWP WHAT TO CONTROL? Control of
More informationGuidance for Industry
Guidance for Industry Process Validation: General Principles and Practices U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
More information3M Drug Delivery Systems. April 26, 2011
3M MDI Manufacturing April 26, 2011 3M Drug Delivery Systems Drug Delivery Systems Overview 3M Drug Delivery Systems is a division of 3M that is dedicated to the development and manufacturing of inhalation
More informationICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Keith O. Webber, Ph.D. Sr. Director, Global Regulator Affairs Rx Perrigo Company, plc Q U A L I T Y A F F
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationDeficiencies found in Inspections and QP Responsibilities
Deficiencies found in Inspections and QP Responsibilities Ciara Turley, HPRA Inspector QP Forum, Trinity College, Dublin 25 th April 2017 Dublin Key QP Responsibilities Chapter 1, 1.4 (xv) Medicinal products
More informationGuidance for Industry Compounding Animal Drugs from Bulk Drug Substances
#230 Guidance for Industry Compounding Animal Drugs from Bulk Drug Substances DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
More informationEffective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs)
Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs) *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! The globalization of the pharmaceutical
More informationIndustry Perspective on PET Manufacturing Comparison of EU and US
Standards for Imaging Endpoints and Manufacturing of PET Radiopharmaceuticals Industry Perspective on PET Manufacturing Comparison of EU and US Guidances and associated Regulations Natcher Conference Center
More informationLABORATORY COMPLIANCE
1 LABORATORY COMPLIANCE Jeanne Moldenhauer Vectech Pharmaceutical Consultants, Inc. Farmington Hills, MI INTRODUCTION Implementation of the Systems-Based Inspection Guideline for drug manufacturers in
More informationCurriculum Vitae. SENIOR VICE PRESIDENT JAMES P. KULLA Mobile Phone:
Curriculum Vitae SENIOR VICE PRESIDENT JAMES P. KULLA Mobile Phone: 240.413.3350 Summary of Qualifications Jim has been active in the medical products industry since 1967. Jim founded a company in 1980
More informationInspection Trends. American Society for Quality Richmond, VA Section March 8, 2016
Inspection Trends American Society for Quality Richmond, VA Section March 8, 2016 Brooke K. Higgins, Senior Policy Advisor CDER / Office of Compliance Office of Manufacturing Quality Division of Drug Quality
More informationInitiation of Validation
Initiation of Validation Design Review Who Validates? What Process to Validate? Process Validation Decision Tree When to Validate? Prospective Validation Concurrent Validation Retrospective Validation
More informationSystems-Based Inspections for Cleaning Validation
Systems-Based Inspections for Cleaning Validation FDA DG 230 July 21, 2014 Rockville, MD Destin A. LeBlanc Cleaning Validation Technologies www.cleaningvalidation.com 1 Cleaning Definition: The process
More informationBest Chemistry Practices to Support the Development of PET Drugs
Best Chemistry Practices to Support the Development of PET Drugs June 10, 2017 8:00 16:00 Organizers and Moderators: Amy Vavere, Ph.D. Steve Zigler, Ph.D. Sponsors: Radiopharmaceutical Sciences Council
More informationBasis for Setting Acceptance Criteria. Basis for setting acceptance criteria
Basis for Setting Acceptance Criteria Representing EBE Brian Withers, Director CMC Regulatory Affairs, Abbott laboratories Basis for setting acceptance criteria Industry considerations: How to allow for
More informationThe ABCs and Challenges of GMP The American Experience
The ABCs and Challenges of GMP The American Experience The Canadian Association of Nuclear Medicine Toronto, Ontario April 22, 2017 Reiko Oyama, R.Ph., B.C.N.P. Washington University School of Medicine
More informationFurther Stability Considerations
Further Stability Considerations Radhika Rajagopalan, Ph.D., Team Leader Chemistry Division 2 Office of Generic Drugs, FDA FDA-GPhA Workshop June 4, 2013 1 Agenda Common considerations Q1D Bracketing and
More informationAnnouncement of the Ministry of Agriculture of People's Republic of China
Announcement of the Ministry of Agriculture of People's Republic of China No.2568 The Detailed Rules on Pesticide Production Permit prepared by the Ministry in accordance with the Regulations on Management
More informationProcess Drift: When Do We Detect it? Richard L. Friedman Director, DMPQ CDER/Office of Compliance PQRI Process Drift Workshop December 1, 2010
Process Drift: When Do We Detect it? Richard L. Friedman Director, DMPQ CDER/Office of Compliance PQRI Process Drift Workshop December 1, 2010 Overview Goal of Manufacturing Central Question: Why is process
More informationEstablished Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry
Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More information